New patent approvals for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has during the last year received seven additional patent approval notifications.
The United States Patent and Trademark Office (USPTO) has issued three notices of allowance. Two of them relate to positioning features to ensure correct implantation of the company’s Episealer® implants, while the third relates to a system for customising an implant for treatment of damage in an anatomical joint.
The Indian patent office Intellectual Property India has granted the company three new patents in India. One patent covers design automation as part of Episurf’s implant production, one relates to design of surgical drill guides, and the third is for an osteotomy guide as part of Episurf’s technology for ankle implants.
Lastly, the Swedish patent office PRV has during the year approved a patent application for implants of the patellofemoral part of the knee joint, to address dysplastic knees. This is the first approval in this patent family.
“With this, we summarise the year that has passed as a strong year for Episurf’s patent portfolio. While the US market is extremely important for us, we are continuing ensuring proper patent protection for the different products the company has developed, in several markets”, comments Katarina Flodström, COO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 30 December 2024.
Tags: